查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1842328

全球生物相似契約製造市場：市場規模、佔有率和趨勢分析（按供應來源、治療領域、服務和地區分類），細分市場預測（2025-2033 年）

Biosimilar Contract Manufacturing Market Size, Share & Trends Analysis Report By Source (Mammalian, Non-mammalian), By Therapeutic Area (Oncology, Blood Disorders), By Service, By Region, And Segment Forecasts, 2025 - 2033
出版日期: | 出版商: Grand View Research | 英文 180 Pages | 商品交期: 2-10個工作天內

價格

生物相似契約製造：市場概覽

全球生物相似契約製造市場預計在 2024 年達到 78.4 億美元，預計到 2033 年將達到 251.9 億美元，2025 年至 2033 年的複合年成長率為 13.87%。

癌症、糖尿病和自體免疫疾病等慢性疾病的日益普遍，推動了對價格合理的生技藥品的需求。

生物相似藥為昂貴的品牌生技藥品提供了經濟有效的替代方案，因此非常適合醫療保健系統和患者。製藥公司擴大將生物相似藥的生產外包給受託製造廠商(CMO)，以降低營運成本、確保符合監管要求並加快產品上市速度。這種不斷成長的需求，加上重磅生技藥品專利到期，顯著擴大了受託製造服務的市場，使藥物研發人員能夠專注於創新，同時利用 CMO 在大規模、高效能生物相似藥生產方面的專業知識。

此外，單株抗體、胰島素類似物和生長因子等重磅生技藥品的專利到期，為生物相似藥生產商創造了巨大的機會。由於生技藥品市場涉及數十億美元的收入，製藥公司競相開發生物相似藥以搶佔市場佔有率。然而，由於生物製劑生產流程極為複雜，許多公司開始轉向擁有生技藥品開發、規模化生產和法規遵從專業知識的受託製造廠商（CMO）。這一趨勢正在加速外包夥伴關係，從而加快生物相似藥的上市速度，同時降低風險和營運成本，刺激市場成長。

此外，為了滿足日益成長的生物相似藥需求，契約製造）正積極投資於先進的生物製造技術，例如一次性系統、大容量生物反應器和連續生產流程。這些技術進步提高了效率、靈活性和擴充性，吸引製藥公司與CMO合作。同時，CMO也在擴大其全球設施，以符合當地監管標準並支持跨國藥物上市。此類擴建使生物相似藥開發商能夠克服基礎設施限制、降低初始投資成本並加速商業化進程。 CMO日益精湛的技術和全球化的業務佈局使其成為不可或缺的合作夥伴，從​​而推動了市場成長。

此外，美國、歐洲和新興經濟體等主要市場法規環境的改善正在促進生物相似藥的推廣應用。美國FDA和EMA等監管機構已建立簡化的核准途徑，在確保安全性和有效性的同時，也加快了產品進入市場的速度。這個框架鼓勵了對生物相似藥研發的投資，並推動了對高品質生產合作夥伴的需求。受託製造廠商）擁有遵守嚴格監管標準的專業知識，並透過為企業提供合規保證和全球市場進入獲益。隨著全球監管環境的日益明朗，預計企業對CMO在生物相似藥生產方面的依賴程度將會增加，從而進一步推動市場成長。

目錄

第1章 分析方法和範圍

第2章執行摘要

第3章：生物相似藥契約製造市場：促進因素、趨勢與範圍

  • 市場聯動展望
    • 附隨市場展望
  • 市場動態
    • 市場促進因素分析
    • 市場限制因素分析
  • 經營模式分析
  • 產品平臺分析
  • 服務定價模式分析
  • 技術進步
  • 供應鏈分析
  • 生物相似契約製造市場：分析工具
    • 波特五力分析
    • PESTEL分析與SWOT分析

第4章：生物相似契約製造市場：依供應來源分類的估算與趨勢分析

  • 細分儀表板
  • 生物相似契約製造市場：按供應來源分類的差異分析
  • 依供應來源分類（2021-2033 年）
  • 哺乳動物
  • 非哺乳動物

第5章：生物相似契約製造市場：按服務類型分類的估算與趨勢分析

  • 細分儀表板
  • 生物相似契約製造市場：按服務類型分類的差異分析
  • 依服務年資（2021-2033）
  • 重組非糖基化蛋白
  • 重組糖基化蛋白

第6章：生物相似契約製造市場：依治療領域分類的估算與趨勢分析

  • 細分儀表板
  • 生物相似契約製造市場：按治療領域分類的差異分析
  • 依治療領域分類（2021-2033 年）
  • 腫瘤學
  • 血液疾病
  • 生長激素缺乏症
  • 慢性病與自體免疫疾病
  • 類風濕性關節炎
  • 其他

第7章：生物相似契約製造市場：區域估算與趨勢分析

  • 區域展望
  • 生物相似契約製造市場：波動分析（按地區分類）
  • 按地區分類（2021-2033 年）
  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 英國
    • 德國
    • 法國
    • 義大利
    • 西班牙
    • 丹麥
    • 瑞典
    • 挪威
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 韓國
    • 澳洲
    • 泰國
  • 拉丁美洲
    • 巴西
    • 阿根廷
  • 中東和非洲
    • 南非
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 科威特
    • 阿曼
    • 卡達

第8章 競爭情勢

  • 公司分類
    • 市場領導
    • 新興企業
  • 2024年企業市場估值分析（企業熱力圖分析）
  • 主要企業簡介
    • Boehringer Ingelheim GmbH
    • Lonza
    • Rentschler Biopharma SE
    • AGC Biologics
    • ProBioGen
    • FUJIFILM Diosynth Biotechnologies
    • Toyobo Co. Ltd.
    • Samsung Biologics
    • Thermo Fisher Scientific, Inc.
    • Binex Co., Ltd.
    • WuXi Biologics
    • AbbVie, Inc.
    • ADMA Biologics, Inc.
    • Catalent, Inc
    • Cambrex Corporation
    • Pfizer Inc.
    • Siegfried Holding AG
Product Code: GVR-4-68039-970-1

Biosimilar Contract Manufacturing Market Summary

The global biosimilar contract manufacturing market size was estimated at USD 7.84 billion in 2024 and is projected to reach USD 25.19 billion by 2033, growing at a CAGR of 13.87% from 2025 to 2033. The increasing prevalence of chronic diseases such as cancer, diabetes, and autoimmune disorders is driving demand for affordable biologics.

Biosimilars offer cost-effective alternatives to expensive branded biologics, making them highly suitable for healthcare systems and patients. Pharmaceutical companies are increasingly outsourcing biosimilar production to contract manufacturing organizations (CMOs) to reduce operational costs, ensure regulatory compliance, and accelerate time-to-market. This growing demand and patent expirations of blockbuster biologics fuel strong market expansion for contract manufacturing services, enabling drug developers to focus on innovation while leveraging CMOs' expertise in large-scale, efficient biosimilar production.

In addition, expiration of patents for blockbuster biologics such as monoclonal antibodies, insulin analogs, and growth factors has opened significant opportunities for biosimilar manufacturers. With billions of dollars in biologics revenue at stake, pharmaceutical companies are increasingly racing to develop biosimilars to capture market share. However, due to high production complexity, many companies rely on contract manufacturing organizations (CMOs) with specialized expertise in biologics development, scale-up, and regulatory compliance. This trend accelerates outsourcing partnerships, enabling faster biosimilar launches while reducing risks and operational costs, thereby driving market growth.

Furthermore, contract manufacturing organizations are heavily investing in advanced biomanufacturing technologies, including single-use systems, high-capacity bioreactors, and continuous processing, to meet the rising demand for biosimilars. These technological advancements enhance efficiency, flexibility, and scalability, attracting pharmaceutical companies to partner with CMOs. In addition, CMOs are expanding global facilities to comply with regional regulatory standards, supporting multinational drug launches. Such expansions enable biosimilar developers to overcome infrastructure limitations, reduce upfront investment costs, and accelerate commercialization timelines. The increasing sophistication and global footprint of CMOs make them indispensable partners, propelling market growth.

Besides these, supportive regulatory environments in key markets such as the U.S., Europe, and emerging economies are fostering the adoption of biosimilars. Regulatory agencies such as the U.S. FDA and EMA have established streamlined approval pathways, ensuring safety and efficacy while expediting market entry. These frameworks encourage investment in biosimilar development, driving demand for high-quality manufacturing partners. Contract manufacturing organizations benefit from their expertise in adhering to stringent regulatory standards, providing companies with compliance assurance and global market access. As regulatory clarity improves worldwide, the reliance on CMOs for biosimilar production is expected to intensify, boosting market growth further.

Global Biosimilar Contract Manufacturing Market Report Segmentation

This report forecasts revenue growth at regional and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global biosimilar contract manufacturing market report based on source, service, therapeutic area, and region

  • Source Outlook (Revenue, USD Million, 2021 - 2033)
  • Mammalian
  • Non-mammalian
  • Service Outlook (Revenue, USD Million, 2021 - 2033)
  • Recombinant Non-glycosylated Proteins
  • Recombinant Glycosylated Proteins
  • Therapeutic Area Outlook (Revenue, USD Million, 2021 - 2033)
  • Oncology
  • Blood Disorders
  • Growth Hormonal Deficiency
  • Chronic & Autoimmune Disorders
  • Rheumatoid Arthritis
  • Others
  • Regional Outlook (Revenue, USD Million, 2021 - 2033)
  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • UK
    • Germany
    • France
    • Italy
    • Spain
    • Denmark
    • Sweden
    • Norway
  • Asia Pacific
    • India
    • China
    • Japan
    • South Korea
    • Australia
    • Thailand
  • Latin America
    • Brazil
    • Argentina
  • Middle East and Africa (MEA)
    • South Africa
    • Saudi Arabia
    • UAE
    • Kuwait
    • Oman
    • Qatar

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation and Scope
  • 1.2. Market Definitions
  • 1.3. Research Methodology
  • 1.4. Information Procurement
    • 1.4.1. Purchased database
    • 1.4.2. GVR's internal database
    • 1.4.3. Secondary sources
    • 1.4.4. Primary research
  • 1.5. Information or Data Analysis
    • 1.5.1. Data analysis models
  • 1.6. Market Formulation & Validation
  • 1.7. Model Details
    • 1.7.1. Commodity flow analysis (Model 1)
    • 1.7.2. Value chain based analysis (Model 2)
    • 1.7.3. Multivariate Analysis (Model 3)
  • 1.8. List of Secondary Sources
  • 1.9. List of Primary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
  • 2.3. Competitive Insights

Chapter 3. Biosimilar Contract Manufacturing Market Variables, Trends, & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Ancillary Market Outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market Driver Analysis
    • 3.2.2. Market Restraint Analysis
  • 3.3. Business Model Analysis
  • 3.4. Product Pipeline Analysis
  • 3.5. Service Pricing Model Analysis
  • 3.6. Technological Advancements
  • 3.7. Supply Chain Analysis
  • 3.8. Biosimilar Contract Manufacturing Market Analysis Tools
    • 3.8.1. Porter's Five Forces Analysis
    • 3.8.2. PESTEL by SWOT Analysis

Chapter 4. Biosimilar Contract Manufacturing Market: Source Estimates & Trend Analysis

  • 4.1. Segment Dashboard
  • 4.2. Biosimilar Contract Manufacturing Market: Source Movement Analysis
  • 4.3. Biosimilar Contract Manufacturing Market Estimates and Forecasts, by Source, 2021 - 2033 (USD Million)
  • 4.4. Mammalian
    • 4.4.1. Mammalian Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 4.5. Non-mammalian
    • 4.5.1. Non-mammalian Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 5. Biosimilar Contract Manufacturing Market: Service Estimates & Trend Analysis

  • 5.1. Segment Dashboard
  • 5.2. Biosimilar Contract Manufacturing Market: Service Movement Analysis
  • 5.3. Biosimilar Contract Manufacturing Market Estimates and Forecasts, by Service, 2021 - 2033 (USD Million)
  • 5.4. Recombinant Non-glycosylated Proteins
    • 5.4.1. Recombinant Non-glycosylated Proteins Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 5.5. Recombinant Glycosylated Proteins
    • 5.5.1. Recombinant Glycosylated Proteins Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 6. Biosimilar Contract Manufacturing Market: Therapeutic Area Estimates & Trend Analysis

  • 6.1. Segment Dashboard
  • 6.2. Biosimilar Contract Manufacturing Market: Therapeutic Area Movement Analysis
  • 6.3. Biosimilar Contract Manufacturing Market Estimates and Forecasts, by Therapeutic Area, 2021 - 2033 (USD Million)
  • 6.4. Oncology
    • 6.4.1. Oncology Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.5. Blood Disorders
    • 6.5.1. Blood Disorders Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.6. Growth Hormonal Deficiency
    • 6.6.1. Growth Hormonal Deficiency Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.7. Chronic & Autoimmune Disorders
    • 6.7.1. Chronic & Autoimmune Disorders Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.8. Rheumatoid Arthritis
    • 6.8.1. Rheumatoid Arthritis Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.9. Others
    • 6.9.1. Others Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 7. Biosimilar Contract Manufacturing Market: Regional Estimates & Trend Analysis

  • 7.1. Regional Outlook
  • 7.2. Biosimilar Contract Manufacturing Market: Regional Movement Analysis
  • 7.3. Biosimilar Contract Manufacturing Market Estimates and Forecasts, by Region, 2021 - 2033 (USD Million)
  • 7.4. North America
    • 7.4.1. North America Biosimilar Contract Manufacturing Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.4.2. U.S.
      • 7.4.2.1. Key Country Dynamics
      • 7.4.2.2. Competitive Scenario
      • 7.4.2.3. Regulatory Framework
      • 7.4.2.4. U.S. Biosimilar Contract Manufacturing Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.4.3. Canada
      • 7.4.3.1. Key Country Dynamics
      • 7.4.3.2. Competitive Scenario
      • 7.4.3.3. Regulatory Framework
      • 7.4.3.4. Canada Biosimilar Contract Manufacturing Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.4.4. Mexico
      • 7.4.4.1. Key Country Dynamics
      • 7.4.4.2. Competitive Scenario
      • 7.4.4.3. Regulatory Framework
      • 7.4.4.4. Mexico Biosimilar Contract Manufacturing Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.5. Europe
    • 7.5.1. Europe Biosimilar Contract Manufacturing Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.5.2. UK
      • 7.5.2.1. Key Country Dynamics
      • 7.5.2.2. Competitive Scenario
      • 7.5.2.3. Regulatory Framework
      • 7.5.2.4. UK Biosimilar Contract Manufacturing Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.5.3. Germany
      • 7.5.3.1. Key Country Dynamics
      • 7.5.3.2. Competitive Scenario
      • 7.5.3.3. Regulatory Framework
      • 7.5.3.4. Germany Biosimilar Contract Manufacturing Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.5.4. France
      • 7.5.4.1. Key Country Dynamics
      • 7.5.4.2. Competitive Scenario
      • 7.5.4.3. Regulatory Framework
      • 7.5.4.4. France Biosimilar Contract Manufacturing Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.5.5. Italy
      • 7.5.5.1. Key Country Dynamics
      • 7.5.5.2. Competitive Scenario
      • 7.5.5.3. Regulatory Framework
      • 7.5.5.4. Italy Biosimilar Contract Manufacturing Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.5.6. Spain
      • 7.5.6.1. Key Country Dynamics
      • 7.5.6.2. Competitive Scenario
      • 7.5.6.3. Regulatory Framework
      • 7.5.6.4. Spain Biosimilar Contract Manufacturing Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.5.7. Denmark
      • 7.5.7.1. Key Country Dynamics
      • 7.5.7.2. Competitive Scenario
      • 7.5.7.3. Regulatory Framework
      • 7.5.7.4. Denmark Biosimilar Contract Manufacturing Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.5.8. Sweden
      • 7.5.8.1. Key Country Dynamics
      • 7.5.8.2. Competitive Scenario
      • 7.5.8.3. Regulatory Framework
      • 7.5.8.4. Sweden Biosimilar Contract Manufacturing Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.5.9. Norway
      • 7.5.9.1. Key Country Dynamics
      • 7.5.9.2. Competitive Scenario
      • 7.5.9.3. Regulatory Framework
      • 7.5.9.4. Norway Biosimilar Contract Manufacturing Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.6. Asia Pacific
    • 7.6.1. Asia Pacific Biosimilar Contract Manufacturing Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.6.2. Japan
      • 7.6.2.1. Key Country Dynamics
      • 7.6.2.2. Competitive Scenario
      • 7.6.2.3. Regulatory Framework
      • 7.6.2.4. Japan Biosimilar Contract Manufacturing Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.6.3. China
      • 7.6.3.1. Key Country Dynamics
      • 7.6.3.2. Competitive Scenario
      • 7.6.3.3. Regulatory Framework
      • 7.6.3.4. China Biosimilar Contract Manufacturing Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.6.4. India
      • 7.6.4.1. Key Country Dynamics
      • 7.6.4.2. Competitive Scenario
      • 7.6.4.3. Regulatory Framework
      • 7.6.4.4. India Biosimilar Contract Manufacturing Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.6.5. South Korea
      • 7.6.5.1. Key Country Dynamics
      • 7.6.5.2. Competitive Scenario
      • 7.6.5.3. Regulatory Framework
      • 7.6.5.4. South Korea Biosimilar Contract Manufacturing Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.6.6. Australia
      • 7.6.6.1. Key Country Dynamics
      • 7.6.6.2. Competitive Scenario
      • 7.6.6.3. Regulatory Framework
      • 7.6.6.4. Australia Biosimilar Contract Manufacturing Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.6.7. Thailand
      • 7.6.7.1. Key Country Dynamics
      • 7.6.7.2. Competitive Scenario
      • 7.6.7.3. Regulatory Framework
      • 7.6.7.4. Thailand Biosimilar Contract Manufacturing Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.7. Latin America
    • 7.7.1. Latin America Biosimilar Contract Manufacturing Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.7.2. Brazil
      • 7.7.2.1. Key Country Dynamics
      • 7.7.2.2. Competitive Scenario
      • 7.7.2.3. Regulatory Framework
      • 7.7.2.4. Brazil Biosimilar Contract Manufacturing Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.7.3. Argentina
      • 7.7.3.1. Key Country Dynamics
      • 7.7.3.2. Competitive Scenario
      • 7.7.3.3. Regulatory Framework
      • 7.7.3.4. Argentina Biosimilar Contract Manufacturing Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.8. Middle East & Africa
    • 7.8.1. Middle East & Africa Biosimilar Contract Manufacturing Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.8.2. South Africa
      • 7.8.2.1. Key Country Dynamics
      • 7.8.2.2. Competitive Scenario
      • 7.8.2.3. Regulatory Framework
      • 7.8.2.4. South Africa Biosimilar Contract Manufacturing Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.8.3. Saudi Arabia
      • 7.8.3.1. Key Country Dynamics
      • 7.8.3.2. Competitive Scenario
      • 7.8.3.3. Regulatory Framework
      • 7.8.3.4. Saudi Arabia Biosimilar Contract Manufacturing Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.8.4. UAE
      • 7.8.4.1. Key Country Dynamics
      • 7.8.4.2. Competitive Scenario
      • 7.8.4.3. Regulatory Framework
      • 7.8.4.4. UAE Biosimilar Contract Manufacturing Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.8.5. Kuwait
      • 7.8.5.1. Key Country Dynamics
      • 7.8.5.2. Competitive Scenario
      • 7.8.5.3. Regulatory Framework
      • 7.8.5.4. Kuwait Biosimilar Contract Manufacturing Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.8.6. Oman
      • 7.8.6.1. Key Country Dynamics
      • 7.8.6.2. Competitive Scenario
      • 7.8.6.3. Regulatory Framework
      • 7.8.6.4. Oman Biosimilar Contract Manufacturing Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.8.7. Qatar
      • 7.8.7.1. Key Country Dynamics
      • 7.8.7.2. Competitive Scenario
      • 7.8.7.3. Regulatory Framework
      • 7.8.7.4. Qatar Biosimilar Contract Manufacturing Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 8. Competitive Landscape

  • 8.1. Company Categorization
    • 8.1.1. Market Leaders
    • 8.1.2. Emerging Players
  • 8.2. Company Market Assessment Analysis, 2024 (Company Heat Map Analysis)
  • 8.3. Key Company Profiles
    • 8.3.1. Boehringer Ingelheim GmbH
      • 8.3.1.1. Company Overview
      • 8.3.1.2. Financial Performance
      • 8.3.1.3. Product Benchmarking
      • 8.3.1.4. Strategic Initiatives
    • 8.3.2. Lonza
      • 8.3.2.1. Company Overview
      • 8.3.2.2. Financial Performance
      • 8.3.2.3. Product Benchmarking
      • 8.3.2.4. Strategic Initiatives
    • 8.3.3. Rentschler Biopharma SE
      • 8.3.3.1. Company Overview
      • 8.3.3.2. Financial Performance
      • 8.3.3.3. Product Benchmarking
      • 8.3.3.4. Strategic Initiatives
    • 8.3.4. AGC Biologics
      • 8.3.4.1. Company Overview
      • 8.3.4.2. Financial Performance
      • 8.3.4.3. Product Benchmarking
      • 8.3.4.4. Strategic Initiatives
    • 8.3.5. ProBioGen
      • 8.3.5.1. Company Overview
      • 8.3.5.2. Financial Performance
      • 8.3.5.3. Product Benchmarking
      • 8.3.5.4. Strategic Initiatives
    • 8.3.6. FUJIFILM Diosynth Biotechnologies
      • 8.3.6.1. Company Overview
      • 8.3.6.2. Financial Performance
      • 8.3.6.3. Product Benchmarking
      • 8.3.6.4. Strategic Initiatives
    • 8.3.7. Toyobo Co. Ltd.
      • 8.3.7.1. Company Overview
      • 8.3.7.2. Financial Performance
      • 8.3.7.3. Product Benchmarking
      • 8.3.7.4. Strategic Initiatives
    • 8.3.8. Samsung Biologics
      • 8.3.8.1. Company Overview
      • 8.3.8.2. Financial Performance
      • 8.3.8.3. Product Benchmarking
      • 8.3.8.4. Strategic Initiatives
    • 8.3.9. Thermo Fisher Scientific, Inc.
      • 8.3.9.1. Company Overview
      • 8.3.9.2. Financial Performance
      • 8.3.9.3. Product Benchmarking
      • 8.3.9.4. Strategic Initiatives
    • 8.3.10. Binex Co., Ltd.
      • 8.3.10.1. Company Overview
      • 8.3.10.2. Financial Performance
      • 8.3.10.3. Product Benchmarking
      • 8.3.10.4. Strategic Initiatives
    • 8.3.11. WuXi Biologics
      • 8.3.11.1. Company Overview
      • 8.3.11.2. Financial Performance
      • 8.3.11.3. Product Benchmarking
      • 8.3.11.4. Strategic Initiatives
    • 8.3.12. AbbVie, Inc.
      • 8.3.12.1. Company Overview
      • 8.3.12.2. Financial Performance
      • 8.3.12.3. Product Benchmarking
      • 8.3.12.4. Strategic Initiatives
    • 8.3.13. ADMA Biologics, Inc.
      • 8.3.13.1. Company Overview
      • 8.3.13.2. Financial Performance
      • 8.3.13.3. Product Benchmarking
      • 8.3.13.4. Strategic Initiatives
    • 8.3.14. Catalent, Inc
      • 8.3.14.1. Company Overview
      • 8.3.14.2. Financial Performance
      • 8.3.14.3. Product Benchmarking
      • 8.3.14.4. Strategic Initiatives
    • 8.3.15. Cambrex Corporation
      • 8.3.15.1. Company Overview
      • 8.3.15.2. Financial Performance
      • 8.3.15.3. Product Benchmarking
      • 8.3.15.4. Strategic Initiatives
    • 8.3.16. Pfizer Inc.
      • 8.3.16.1. Company Overview
      • 8.3.16.2. Financial Performance
      • 8.3.16.3. Product Benchmarking
      • 8.3.16.4. Strategic Initiatives
    • 8.3.17. Siegfried Holding AG
      • 8.3.17.1. Company Overview
      • 8.3.17.2. Financial Performance
      • 8.3.17.3. Product Benchmarking
      • 8.3.17.4. Strategic Initiatives

List of Tables

  • Table 1. List of Secondary Sources
  • Table 2. List of Abbreviations
  • Table 3. Global Biosimilar Contract Manufacturing Market Estimates and Forecasts, by Source, 2021 - 2033 (USD Million)
  • Table 4. Global Biosimilar Contract Manufacturing Market Estimates and Forecasts, Therapeutic Area, 2021 - 2033 (USD Million)
  • Table 5. Global Biosimilar Contract Manufacturing Market Estimates and Forecasts, by Service, 2021 - 2033 (USD Million)
  • Table 6. Global Biosimilar Contract Manufacturing Market Estimates and Forecasts, by Region, 2021 - 2033 (USD Million)
  • Table 7. North America Biosimilar Contract Manufacturing Market Estimates and Forecasts, by Country, 2021 - 2033 (USD Million)
  • Table 8. North America Biosimilar Contract Manufacturing Market Estimates and Forecasts, by Source, 2021 - 2033 (USD Million)
  • Table 9. North America Biosimilar Contract Manufacturing Market Estimates and Forecasts, by Therapeutic Area, 2021 - 2033 (USD Million)
  • Table 10. North America Biosimilar Contract Manufacturing Market Estimates and Forecasts, by Service, 2021 - 2033 (USD Million)
  • Table 11. U.S. Biosimilar Contract Manufacturing Market Estimates and Forecasts, by Source, 2021 - 2033 (USD Million)
  • Table 12. U.S. Biosimilar Contract Manufacturing Market Estimates and Forecasts, by Therapeutic Area, 2021 - 2033 (USD Million)
  • Table 13. U.S. Biosimilar Contract Manufacturing Market Estimates and Forecasts, by Service, 2021 - 2033 (USD Million)
  • Table 14. Canada Biosimilar Contract Manufacturing Market Estimates and Forecasts, by Source, 2021 - 2033 (USD Million)
  • Table 15. Canada Biosimilar Contract Manufacturing Market Estimates and Forecasts, by Therapeutic Area, 2021 - 2033 (USD Million)
  • Table 16. Canada Biosimilar Contract Manufacturing Market Estimates and Forecasts, by Service, 2021 - 2033 (USD Million)
  • Table 17. Mexico Biosimilar Contract Manufacturing Market Estimates and Forecasts, by Source, 2021 - 2033 (USD Million)
  • Table 18. Mexico Biosimilar Contract Manufacturing Market Estimates and Forecasts, by Therapeutic Area, 2021 - 2033 (USD Million)
  • Table 19. Mexico Biosimilar Contract Manufacturing Market Estimates and Forecasts, by Service, 2021 - 2033 (USD Million)
  • Table 20. Europe Biosimilar Contract Manufacturing Market Estimates and Forecasts, by Country, 2021 - 2033 (USD Million)
  • Table 21. Europe Biosimilar Contract Manufacturing Market Estimates and Forecasts, by Source, 2021 - 2033 (USD Million)
  • Table 22. Europe Biosimilar Contract Manufacturing Market Estimates and Forecasts, by Therapeutic Area, 2021 - 2033 (USD Million)
  • Table 23. Europe Biosimilar Contract Manufacturing Market Estimates and Forecasts, by Service, 2021 - 2033 (USD Million)
  • Table 24. Germany Biosimilar Contract Manufacturing Market Estimates and Forecasts, by Source, 2021 - 2033 (USD Million)
  • Table 25. Germany Biosimilar Contract Manufacturing Market Estimates and Forecasts, by Therapeutic Area, 2021 - 2033 (USD Million)
  • Table 26. Germany Biosimilar Contract Manufacturing Market Estimates and Forecasts, by Service, 2021 - 2033 (USD Million)
  • Table 27. UK Biosimilar Contract Manufacturing Market Estimates and Forecasts, by Source, 2021 - 2033 (USD Million)
  • Table 28. UK Biosimilar Contract Manufacturing Market Estimates and Forecasts, by Therapeutic Area, 2021 - 2033 (USD Million)
  • Table 29. UK Biosimilar Contract Manufacturing Market Estimates and Forecasts, by Service, 2021 - 2033 (USD Million)
  • Table 30. France Biosimilar Contract Manufacturing Market Estimates and Forecasts, by Source, 2021 - 2033 (USD Million)
  • Table 31. France Biosimilar Contract Manufacturing Market Estimates and Forecasts, by Therapeutic Area, 2021 - 2033 (USD Million)
  • Table 32. France Biosimilar Contract Manufacturing Market Estimates and Forecasts, by Service, 2021 - 2033 (USD Million)
  • Table 33. Italy Biosimilar Contract Manufacturing Market Estimates and Forecasts, by Source, 2021 - 2033 (USD Million)
  • Table 34. Italy Biosimilar Contract Manufacturing Market Estimates and Forecasts, by Therapeutic Area, 2021 - 2033 (USD Million)
  • Table 35. Italy Biosimilar Contract Manufacturing Market Estimates and Forecasts, by Service, 2021 - 2033 (USD Million)
  • Table 36. Spain Biosimilar Contract Manufacturing Market Estimates and Forecasts, by Source, 2021 - 2033 (USD Million)
  • Table 37. Spain Biosimilar Contract Manufacturing Market Estimates and Forecasts, by Therapeutic Area, 2021 - 2033 (USD Million)
  • Table 38. Spain Biosimilar Contract Manufacturing Market Estimates and Forecasts, by Service, 2021 - 2033 (USD Million)
  • Table 39. Denmark Biosimilar Contract Manufacturing Market Estimates and Forecasts, by Source, 2021 - 2033 (USD Million)
  • Table 40. Denmark Biosimilar Contract Manufacturing Market Estimates and Forecasts, by Therapeutic Area, 2021 - 2033 (USD Million)
  • Table 41. Denmark Biosimilar Contract Manufacturing Market Estimates and Forecasts, by Service, 2021 - 2033 (USD Million)
  • Table 42. Sweden Biosimilar Contract Manufacturing Market Estimates and Forecasts, by Source, 2021 - 2033 (USD Million)
  • Table 43. Sweden Biosimilar Contract Manufacturing Market Estimates and Forecasts, by Therapeutic Area, 2021 - 2033 (USD Million)
  • Table 44. Sweden Biosimilar Contract Manufacturing Market Estimates and Forecasts, by Service, 2021 - 2033 (USD Million)
  • Table 45. Norway Biosimilar Contract Manufacturing Market Estimates and Forecasts, by Source, 2021 - 2033 (USD Million)
  • Table 46. Norway Biosimilar Contract Manufacturing Market Estimates and Forecasts, by Therapeutic Area, 2021 - 2033 (USD Million)
  • Table 47. Norway Biosimilar Contract Manufacturing Market Estimates and Forecasts, by Service, 2021 - 2033 (USD Million)
  • Table 48. Asia Pacific Biosimilar Contract Manufacturing Market Estimates and Forecasts, by Country, 2021 - 2033 (USD Million)
  • Table 49. Asia Pacific Biosimilar Contract Manufacturing Market Estimates and Forecasts, by Source, 2021 - 2033 (USD Million)
  • Table 50. Asia Pacific Biosimilar Contract Manufacturing Market Estimates and Forecasts, by Therapeutic Area, 2021 - 2033 (USD Million)
  • Table 51. Asia Pacific Biosimilar Contract Manufacturing Market Estimates and Forecasts, by Service, 2021 - 2033 (USD Million)
  • Table 52. China Biosimilar Contract Manufacturing Market Estimates and Forecasts, by Source, 2021 - 2033 (USD Million)
  • Table 53. China Biosimilar Contract Manufacturing Market Estimates and Forecasts, by Therapeutic Area, 2021 - 2033 (USD Million)
  • Table 54. China Biosimilar Contract Manufacturing Market Estimates and Forecasts, by Service, 2021 - 2033 (USD Million)
  • Table 55. Japan Biosimilar Contract Manufacturing Market Estimates and Forecasts, by Source, 2021 - 2033 (USD Million)
  • Table 56. Japan Biosimilar Contract Manufacturing Market Estimates and Forecasts, by Therapeutic Area, 2021 - 2033 (USD Million)
  • Table 57. Japan Biosimilar Contract Manufacturing Market Estimates and Forecasts, by Service, 2021 - 2033 (USD Million)
  • Table 58. India Biosimilar Contract Manufacturing Market Estimates and Forecasts, by Source, 2021 - 2033 (USD Million)
  • Table 59. India Biosimilar Contract Manufacturing Market Estimates and Forecasts, by Therapeutic Area, 2021 - 2033 (USD Million)
  • Table 60. India Biosimilar Contract Manufacturing Market Estimates and Forecasts, by Service, 2021 - 2033 (USD Million)
  • Table 61. South Korea Biosimilar Contract Manufacturing Market Estimates and Forecasts, by Source, 2021 - 2033 (USD Million)
  • Table 62. South Korea Biosimilar Contract Manufacturing Market Estimates and Forecasts, by Therapeutic Area, 2021 - 2033 (USD Million)
  • Table 63. South Korea Biosimilar Contract Manufacturing Market Estimates and Forecasts, by Service, 2021 - 2033 (USD Million)
  • Table 64. Australia Biosimilar Contract Manufacturing Market Estimates and Forecasts, by Source, 2021 - 2033 (USD Million)
  • Table 65. Australia Biosimilar Contract Manufacturing Market Estimates and Forecasts, by Therapeutic Area, 2021 - 2033 (USD Million)
  • Table 66. Australia Biosimilar Contract Manufacturing Market Estimates and Forecasts, by Service, 2021 - 2033 (USD Million)
  • Table 67. Thailand Biosimilar Contract Manufacturing Market Estimates and Forecasts, by Source, 2021 - 2033 (USD Million)
  • Table 68. Thailand Biosimilar Contract Manufacturing Market Estimates and Forecasts, by Therapeutic Area, 2021 - 2033 (USD Million)
  • Table 69. Thailand Biosimilar Contract Manufacturing Market Estimates and Forecasts, by Service, 2021 - 2033 (USD Million)
  • Table 70. Latin America Biosimilar Contract Manufacturing Market Estimates and Forecasts, by Country, 2021 - 2033 (USD Million)
  • Table 71. Latin America Biosimilar Contract Manufacturing Market Estimates and Forecasts, by Source, 2021 - 2033 (USD Million)
  • Table 72. Latin America Biosimilar Contract Manufacturing Market Estimates and Forecasts, by Therapeutic Area, 2021 - 2033 (USD Million)
  • Table 73. Latin America Biosimilar Contract Manufacturing Market Estimates and Forecasts, by Service, 2021 - 2033 (USD Million)
  • Table 74. Brazil Biosimilar Contract Manufacturing Market Estimates and Forecasts, by Source, 2021 - 2033 (USD Million)
  • Table 75. Brazil Biosimilar Contract Manufacturing Market Estimates and Forecasts, by Therapeutic Area, 2021 - 2033 (USD Million)
  • Table 76. Brazil Biosimilar Contract Manufacturing Market Estimates and Forecasts, by Service, 2021 - 2033 (USD Million)
  • Table 77. Argentina Biosimilar Contract Manufacturing Market Estimates and Forecasts, by Source, 2021 - 2033 (USD Million)
  • Table 78. Argentina Biosimilar Contract Manufacturing Market Estimates and Forecasts, by Therapeutic Area, 2021 - 2033 (USD Million)
  • Table 79. Argentina Biosimilar Contract Manufacturing Market Estimates and Forecasts, by Service, 2021 - 2033 (USD Million)
  • Table 80. Middle East & Africa Biosimilar Contract Manufacturing Market Estimates and Forecasts, by Country, 2021 - 2033 (USD Million)
  • Table 81. Middle East & Africa Biosimilar Contract Manufacturing Market Estimates and Forecasts, by Source, 2021 - 2033 (USD Million)
  • Table 82. Middle East & Africa Biosimilar Contract Manufacturing Market Estimates and Forecasts, by Therapeutic Area, 2021 - 2033 (USD Million)
  • Table 83. Middle East & Africa Biosimilar Contract Manufacturing Market Estimates and Forecasts, by Service, 2021 - 2033 (USD Million)
  • Table 84. South Africa Biosimilar Contract Manufacturing Market Estimates and Forecasts, by Source, 2021 - 2033 (USD Million)
  • Table 85. South Africa Biosimilar Contract Manufacturing Market Estimates and Forecasts, by Therapeutic Area, 2021 - 2033 (USD Million)
  • Table 86. South Africa Biosimilar Contract Manufacturing Market Estimates and Forecasts, by Service, 2021 - 2033 (USD Million)
  • Table 87. Saudi Arabia Biosimilar Contract Manufacturing Market Estimates and Forecasts, by Source, 2021 - 2033 (USD Million)
  • Table 88. Saudi Arabia Biosimilar Contract Manufacturing Market Estimates and Forecasts, by Therapeutic Area, 2021 - 2033 (USD Million)
  • Table 89. Saudi Arabia Biosimilar Contract Manufacturing Market Estimates and Forecasts, by Service, 2021 - 2033 (USD Million)
  • Table 90. UAE Biosimilar Contract Manufacturing Market Estimates and Forecasts, by Source, 2021 - 2033 (USD Million)
  • Table 91. UAE Biosimilar Contract Manufacturing Market Estimates and Forecasts, by Therapeutic Area, 2021 - 2033 (USD Million)
  • Table 92. UAE Biosimilar Contract Manufacturing Market Estimates and Forecasts, by Service, 2021 - 2033 (USD Million)
  • Table 93. Kuwait Biosimilar Contract Manufacturing Market Estimates and Forecasts, by Source, 2021 - 2033 (USD Million)
  • Table 94. Kuwait Biosimilar Contract Manufacturing Market Estimates and Forecasts, by Therapeutic Area, 2021 - 2033 (USD Million)
  • Table 95. Kuwait Biosimilar Contract Manufacturing Market Estimates and Forecasts, by Service, 2021 - 2033 (USD Million)
  • Table 96. Oman Biosimilar Contract Manufacturing Market Estimates and Forecasts, by Source, 2021 - 2033 (USD Million)
  • Table 97. Oman Biosimilar Contract Manufacturing Market Estimates and Forecasts, by Therapeutic Area, 2021 - 2033 (USD Million)
  • Table 98. Oman Biosimilar Contract Manufacturing Market Estimates and Forecasts, by Service, 2021 - 2033 (USD Million)
  • Table 99. Qatar Biosimilar Contract Manufacturing Market Estimates and Forecasts, by Source, 2021 - 2033 (USD Million)
  • Table 100. Qatar Biosimilar Contract Manufacturing Market Estimates and Forecasts, by Therapeutic Area, 2021 - 2033 (USD Million)
  • Table 101. Qatar Biosimilar Contract Manufacturing Market Estimates and Forecasts, by Service, 2021 - 2033 (USD Million)

List of Figures

  • Fig. 1 Biosimilar contract manufacturing market segmentation
  • Fig. 2 Market research process
  • Fig. 3 Information procurement
  • Fig. 4 Primary research pattern
  • Fig. 5 Market research approaches
  • Fig. 6 Value chain-based sizing & forecasting
  • Fig. 7 Market formulation & validation
  • Fig. 8 Market dynamics
  • Fig. 9 Market driver analysis (current & future impact)
  • Fig. 10 Market restraint analysis (current & future impact)
  • Fig. 11 Porter's five forces analysis
  • Fig. 12 PESTEL by SWOT analysis
  • Fig. 13 Biosimilar contract manufacturing source key takeaways (USD Million)
  • Fig. 14 Biosimilar contract manufacturing market: Source, market share 2024 & 2033
  • Fig. 15 Mammalian biosimilar contract manufacturing market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 16 Non-mammalian biosimilar contract manufacturing market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 17 Biosimilar contract manufacturing therapeutic area key takeaways (USD Million)
  • Fig. 18 Biosimilar contract manufacturing market: therapeutic area, market share 2024 & 2033
  • Fig. 19 Oncology biosimilar contract manufacturing market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 20 Blood disorders biosimilar contract manufacturing market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 21 Growth hormonal deficiency biosimilar contract manufacturing market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 22 Chronic & autoimmune disorders biosimilar contract manufacturing market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 23 Rheumatoid arthritis biosimilar contract manufacturing market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 24 Others biosimilar contract manufacturing market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 25 Biosimilar contract manufacturing service key takeaways (USD Million)
  • Fig. 26 Biosimilar contract manufacturing market: service, market share 2024 & 2033
  • Fig. 27 Recombinant non-glycosylated proteins biosimilar contract manufacturing market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 28 Recombinant glycosylated proteins biosimilar contract manufacturing market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 29 Regional outlook, 2024 & 2033
  • Fig. 30 North America biosimilar contract manufacturing market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 31 U.S. biosimilar contract manufacturing market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 32 Canada biosimilar contract manufacturing market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 33 Mexico biosimilar contract manufacturing market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 34 Europe biosimilar contract manufacturing market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 35 UK biosimilar contract manufacturing market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 36 Germany biosimilar contract manufacturing market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 37 France biosimilar contract manufacturing market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 38 Italy biosimilar contract manufacturing market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 39 Spain biosimilar contract manufacturing market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 40 Denmark biosimilar contract manufacturing market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 41 Sweden biosimilar contract manufacturing market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 42 Norway biosimilar contract manufacturing market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 43 Asia Pacific biosimilar contract manufacturing market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 44 Japan biosimilar contract manufacturing market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 45 China biosimilar contract manufacturing market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 46 India biosimilar contract manufacturing market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 47 Australia biosimilar contract manufacturing market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 48 South Korea biosimilar contract manufacturing market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 49 Thailand biosimilar contract manufacturing market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 50 Latin America biosimilar contract manufacturing market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 51 Brazil biosimilar contract manufacturing market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 52 Argentina biosimilar contract manufacturing market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 53 MEA biosimilar contract manufacturing market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 54 South Africa biosimilar contract manufacturing market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 55 Saudi Arabia biosimilar contract manufacturing market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 56 UAE biosimilar contract manufacturing market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 57 Kuwait biosimilar contract manufacturing market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 58 Qatar biosimilar contract manufacturing market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 59 Oman biosimilar contract manufacturing market estimates and forecasts, 2021 - 2033 (USD Million)